Higgs, Brandon W.
AstraZeneca (United States)
3 papers on CoChatORCID 0000-0002-2951-0245
Most cited papers
- Verified
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
Rizvi, N. A., Cho, B. C., Reinmuth, N., Lee, K. H., Luft, A., Ahn, M.-J., van den Heuvel, M. M., Cobo, M., Vicente, D., Smolin, A., et al. (2020) · JAMA Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 623
- Verified
Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction
Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell
vaccines and immunoinformatics approachesCancer Immunotherapy and Biomarkers
Cited by 538
- Verified
Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade
Zhang, Q., Luo, J., Wu, S., Si, H., Gao, C., Xu, W., Abdullah, S. E., Higgs, B. W., Dennis, P. A., van der Heijden, M. S., et al. (2020) · Cancer Discovery
Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics
Cited by 348
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free